FI961466A - Mykofenolaattimofetiilin oraaliset suurannossuspensiot - Google Patents

Mykofenolaattimofetiilin oraaliset suurannossuspensiot Download PDF

Info

Publication number
FI961466A
FI961466A FI961466A FI961466A FI961466A FI 961466 A FI961466 A FI 961466A FI 961466 A FI961466 A FI 961466A FI 961466 A FI961466 A FI 961466A FI 961466 A FI961466 A FI 961466A
Authority
FI
Finland
Prior art keywords
high dose
mycophenolate mofetil
oral high
dose suspensions
suspensions
Prior art date
Application number
FI961466A
Other languages
English (en)
Swedish (sv)
Other versions
FI116773B (fi
FI961466A0 (fi
Inventor
Deborah M Lidgate
Li-Hua Wang-Kessler
Bindu Joshi
Sayee G Hegde
Leo Gu
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of FI961466A publication Critical patent/FI961466A/fi
Publication of FI961466A0 publication Critical patent/FI961466A0/fi
Application granted granted Critical
Publication of FI116773B publication Critical patent/FI116773B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Harvesting Machines For Root Crops (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI961466A 1993-10-01 1996-04-01 Menetelmä mykofenolaattimofetiilin oraalisten suurannossuspensioiden valmistamiseksi FI116773B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13034393A 1993-10-01 1993-10-01
US13034393 1993-10-01
PCT/US1994/010926 WO1995009626A1 (en) 1993-10-01 1994-09-27 Mycophenolate mofetil high dose oral suspensions
US9410926 1994-09-27

Publications (3)

Publication Number Publication Date
FI961466A true FI961466A (fi) 1996-04-01
FI961466A0 FI961466A0 (fi) 1996-04-01
FI116773B FI116773B (fi) 2006-02-28

Family

ID=22444241

Family Applications (2)

Application Number Title Priority Date Filing Date
FI961466A FI116773B (fi) 1993-10-01 1996-04-01 Menetelmä mykofenolaattimofetiilin oraalisten suurannossuspensioiden valmistamiseksi
FI20060003A FI117502B (fi) 1993-10-01 2006-01-02 Menetelmä mykofenolaattimofetiilin kuivien suurannosgranulaattien valmistamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20060003A FI117502B (fi) 1993-10-01 2006-01-02 Menetelmä mykofenolaattimofetiilin kuivien suurannosgranulaattien valmistamiseksi

Country Status (28)

Country Link
US (1) US5688529A (fi)
EP (2) EP1475091A1 (fi)
JP (1) JP3844491B2 (fi)
CN (1) CN1089583C (fi)
AT (1) ATE303143T1 (fi)
AU (1) AU678303B2 (fi)
BR (1) BR9407728A (fi)
CZ (2) CZ301771B6 (fi)
DE (1) DE69434474T2 (fi)
DK (1) DK0721335T3 (fi)
ES (1) ES2248793T3 (fi)
FI (2) FI116773B (fi)
HK (1) HK1012583A1 (fi)
HU (1) HU228672B1 (fi)
IL (1) IL111116A (fi)
LT (1) LT4099B (fi)
LV (1) LV11428B (fi)
NO (1) NO310673B1 (fi)
NZ (1) NZ274678A (fi)
PL (1) PL177323B1 (fi)
PT (1) PT721335E (fi)
RO (1) RO115412B1 (fi)
RU (1) RU2150942C1 (fi)
SG (1) SG55007A1 (fi)
TW (1) TW427914B (fi)
UA (1) UA39962C2 (fi)
WO (1) WO1995009626A1 (fi)
ZA (1) ZA947683B (fi)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5843470A (en) 1995-10-06 1998-12-01 Mdv Technologies, Inc. Method and composition for inhibiting post-surgical adhesions
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
EP1039932A1 (en) * 1997-12-23 2000-10-04 Alliance Pharmaceutical Corporation Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
WO2000015210A2 (en) * 1998-09-14 2000-03-23 Vertex Pharmaceuticals Incorporated Use of mycophenol acid and its derivatives for the treatment of virus diseases
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
NZ515675A (en) 1999-05-14 2004-06-25 Nereus Pharmaceuticals Inc Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
US6726922B1 (en) 1999-06-28 2004-04-27 Minu, L.L.C. Process and composition for temporarily suppressing pain
CA2400642A1 (en) * 2000-02-23 2001-08-30 Vertex Pharmaceuticals (San Diego) Llc Modified fluorescent proteins
AU4322802A (en) * 2000-11-16 2002-06-24 Univ California Marine actinomycete taxon for drug and fermentation product dicovery
FR2819721B1 (fr) * 2001-01-19 2005-02-04 L M D Traitement des escarres avec sucre non metabolisable et un absorbant polymerique
ES2243457T3 (es) * 2001-01-23 2005-12-01 Gador S.A. Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma.
ES2266084T3 (es) * 2001-02-14 2007-03-01 Forte Iq B.V. Composicion farmaceutica que comprende una goma de xantano.
ATE243028T1 (de) 2001-07-11 2003-07-15 Applied Pharma Res Fettlösliche substanzen enthaltende granulate und verfahren zu ihrer herstellung
JP2005504815A (ja) * 2001-10-02 2005-02-17 スミスクライン・ビーチャム・コーポレイション カルベジロールの新規組成物
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US20040127435A1 (en) * 2002-08-02 2004-07-01 Regents Of The University Of California Uses for inhibitors of inosine monophosphate dehydrogenase
AU2003296908A1 (en) * 2002-09-27 2004-05-04 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
NZ544588A (en) * 2003-06-20 2010-06-25 Nereus Pharmaceuticals Inc Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
TWI369184B (en) * 2003-09-12 2012-08-01 Ryukakusan Co Ltd A granular jelly drink capable of masking bitter
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7087369B2 (en) * 2003-12-17 2006-08-08 The Regents Of The University Of California Cornea preservation medium
EP1711486B1 (en) * 2004-01-23 2011-05-11 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobial agents
EP1740564A2 (en) * 2004-04-26 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105769A2 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - Mycophenolate mofetil impurity
EP1812443A2 (en) 2004-04-30 2007-08-01 Nereus Pharmaceuticals, Inc. [3.2.0] heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006004795A2 (en) * 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
WO2006012385A2 (en) * 2004-07-20 2006-02-02 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Crystalline mycophenolate sodium
US20060051428A1 (en) * 2004-09-03 2006-03-09 Nelson Ayala Aspartame and citrate flavored phosphate salt laxative
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070225350A1 (en) * 2004-12-03 2007-09-27 Anderson Kenneth C Compositions and methods for treating neoplastic diseases
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
WO2007015757A2 (en) 2005-07-21 2007-02-08 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
US20070082061A1 (en) * 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
JP2009526771A (ja) * 2006-02-13 2009-07-23 ノバルティス アクチエンゲゼルシャフト 高投与量のミコフェノール酸（ｍｐａ）
US7985429B2 (en) 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
GB0612809D0 (en) * 2006-06-28 2006-08-09 Univ Sunderland Formulation
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
KR101465836B1 (ko) * 2007-10-12 2014-11-26 류가쿠산 가부시키가이샤 약복용 입상 젤리 음료 및 그 제조 방법
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
MX2010012341A (es) 2008-05-12 2010-12-06 Nereus Pharmaceuticals Inc Derivados de salinosporamida como inhibidores de proteasoma.
JP2011527339A (ja) * 2008-07-09 2011-10-27 アスプレバ インターナショナル リミテッド 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液
CN101671706B (zh) * 2009-09-05 2013-09-18 山东新时代药业有限公司 一种霉酚酸发酵过程中补糖方法
CA2773249A1 (en) * 2009-09-10 2011-03-17 Bial-Portela & C.A., S.A. Oral suspension formulations of esclicarbazepine acetate
US20130005722A1 (en) * 2010-03-23 2013-01-03 Manoj Senapati Pharmaceutical Composition of Mycophenolate Mofetil and Process for Preparing Thereof
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
MX2017002750A (es) 2014-09-02 2017-08-02 Singh Bhupinder Metodo para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
IL251588B2 (en) 2014-10-08 2024-09-01 Pacific Northwest Res Institute Methods and preparations for increasing the potency of antifungal agents
TW201615186A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 脫克鈣藥物應用於癌症治療
US12011429B2 (en) 2016-06-02 2024-06-18 Steven Baranowitz Prevention and treatment of viral infections
CA3026241A1 (en) 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections
US10603299B2 (en) 2016-06-02 2020-03-31 Steven Baranowitz Prevention and treatment of viral infections
WO2018167628A1 (en) * 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN112533614A (zh) 2018-03-28 2021-03-19 美国康宝莱国际公司 多糖的乙酰化
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
CN112315962B (zh) * 2020-11-17 2022-03-29 北京化工大学 霉酚酸在治疗和预防柯萨奇病毒感染中的应用
CN117883379A (zh) * 2021-02-12 2024-04-16 浙江贝灵生物医药有限公司 一种口服碱性溶媒组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
ZA717826B (en) * 1970-11-27 1973-06-27 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
CH653550A5 (de) * 1981-10-20 1986-01-15 Sandoz Ag Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4727069A (en) 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
DE69129459T2 (de) * 1990-08-10 1998-10-15 Anormed Inc Immunosuppressive zusammensetzungen
US5247083A (en) 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid

Also Published As

Publication number Publication date
SG55007A1 (en) 1998-12-21
BR9407728A (pt) 1997-02-12
WO1995009626A1 (en) 1995-04-13
NZ274678A (en) 1999-07-29
CN1089583C (zh) 2002-08-28
ES2248793T3 (es) 2006-03-16
NO310673B1 (no) 2001-08-13
JPH09509648A (ja) 1997-09-30
LT96039A (en) 1996-10-25
EP0721335A1 (en) 1996-07-17
IL111116A (en) 1998-04-05
PL177323B1 (pl) 1999-10-29
NO961325L (no) 1996-04-01
LV11428B (en) 1996-12-20
PL313772A1 (en) 1996-07-22
RO115412B1 (ro) 2000-02-28
CZ291231B6 (cs) 2003-01-15
UA39962C2 (uk) 2001-07-16
EP1475091A1 (en) 2004-11-10
RU2150942C1 (ru) 2000-06-20
AU678303B2 (en) 1997-05-22
IL111116A0 (en) 1994-11-28
CZ301771B6 (cs) 2010-06-16
HK1012583A1 (en) 1999-08-06
DE69434474D1 (de) 2005-10-06
HU228672B1 (en) 2013-05-28
ZA947683B (en) 1996-04-01
HUT73675A (en) 1996-09-30
NO961325D0 (no) 1996-04-01
DE69434474T2 (de) 2006-05-18
LV11428A (lv) 1996-08-20
JP3844491B2 (ja) 2006-11-15
US5688529A (en) 1997-11-18
EP0721335B1 (en) 2005-08-31
CN1132479A (zh) 1996-10-02
PT721335E (pt) 2005-11-30
FI117502B (fi) 2006-11-15
TW427914B (en) 2001-04-01
LT4099B (en) 1997-01-27
DK0721335T3 (da) 2006-01-09
CZ95496A3 (en) 1996-06-12
HU9600838D0 (en) 1996-05-28
FI116773B (fi) 2006-02-28
FI20060003A (fi) 2006-01-02
AU7920594A (en) 1995-05-01
ATE303143T1 (de) 2005-09-15
FI961466A0 (fi) 1996-04-01

Similar Documents

Publication Publication Date Title
FI961466A (fi) Mykofenolaattimofetiilin oraaliset suurannossuspensiot
ES2104605T3 (es) Composiciones estables de acido ascorbico.
ES2064634T3 (es) Suspension farmaceutica acuosa para agentes activos farmaceuticos esencialmente insolubles en agua.
NO912758L (no) Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger.
FR2666508B1 (fr) Compositions pharmaceutiques contenant des derives de furanne.
ATE65025T1 (de) Kalziumkarbonatsuspension enthaltende pharmazeutische zusammensetzung.
ES2001856A6 (es) Una composicion acuosa basica de isotiazolonas n-insustituidas
ATE204752T1 (de) Therapeutische anwendungen von 2',5'- oligoadenylat-derivaten
CA2172506A1 (en) Mycophenolate mofetil and mycophenolic acid high dose oral suspensions
IT1198238B (it) Composti ad attivita' antibiotica
SE8605050D0 (sv) Anvendning av tetrahydrobensotienylkarbamid-derivat som fungicider
RU93051781A (ru) Бета -фенилизосерин-(2r,3s) и его соли, способ его получения и его применения
UA27821C2 (uk) Похідні ізатину або ізатиноксиму, що мають активність, пов'язану з блокадою рецепторів глутамінової та аспарагінової кислот, спосіб їх одержання, фармацевтична композиція та спосіб лікування

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116773

Country of ref document: FI

MA Patent expired